A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

NCT07207395 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

DRUG: JBI-802
DRUG: Pembrolizumab

Sponsor

The Christ Hospital